These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 24975673)

  • 1. Proteoglycans and glycosaminoglycans in misfolded proteins formation in Alzheimer's disease.
    Wang P; Ding K
    Protein Pept Lett; 2014; 21(10):1048-56. PubMed ID: 24975673
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of proteoglycans and glycosaminoglycans in the pathogenesis of Alzheimer's disease and related disorders: amyloidogenesis and therapeutic strategies--a review.
    Ariga T; Miyatake T; Yu RK
    J Neurosci Res; 2010 Aug; 88(11):2303-15. PubMed ID: 20623617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.
    Lin LF; Luo HM
    Neurosci Bull; 2011 Feb; 27(1):53-60. PubMed ID: 21270904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of amyloid-β aggregation in Alzheimer's disease.
    Wang Q; Yu X; Li L; Zheng J
    Curr Pharm Des; 2014; 20(8):1223-43. PubMed ID: 23713775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset.
    Dionísio PA; Amaral JD; Ribeiro MF; Lo AC; D'Hooge R; Rodrigues CM
    Neurobiol Aging; 2015 Jan; 36(1):228-40. PubMed ID: 25443293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of anionic peptide fragments in 1N4R human tau protein aggregation.
    Khalili MA; Riazi G; Ahmadian S; Khodarahmi R; Khodadadi S; Afrasiabi A; Karima O; Mokhtari F; Hoveizi E
    Protein Pept Lett; 2014 Jun; 21(6):511-6. PubMed ID: 24364857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Unifying Hypothesis of Alzheimer's Disease: Heparan Sulfate Proteoglycans/Glycosaminoglycans Are Key as First Hypothesized Over 30 Years Ago.
    Snow AD; Cummings JA; Lake T
    Front Aging Neurosci; 2021; 13():710683. PubMed ID: 34671250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NABi, a novel β-sheet breaker, inhibits Aβ aggregation and neuronal toxicity: Therapeutic implications for Alzheimer's disease.
    Jang JY; Rhim H; Kang S
    Biochim Biophys Acta Gen Subj; 2018 Jan; 1862(1):71-80. PubMed ID: 29107146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau Biology and Tau-Directed Therapies for Alzheimer's Disease.
    Bakota L; Brandt R
    Drugs; 2016 Mar; 76(3):301-13. PubMed ID: 26729186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for Alzheimer's disease.
    Wang W; Fan L; Xu D; Wen Z; Yu R; Ma Q
    Acta Biochim Biophys Sin (Shanghai); 2012 Oct; 44(10):807-14. PubMed ID: 22899646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Untangling amyloid-β, tau, and metals in Alzheimer's disease.
    Savelieff MG; Lee S; Liu Y; Lim MH
    ACS Chem Biol; 2013 May; 8(5):856-65. PubMed ID: 23506614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current thinking on the mechanistic basis of Alzheimer's and implications for drug development.
    Ising C; Stanley M; Holtzman DM
    Clin Pharmacol Ther; 2015 Nov; 98(5):469-71. PubMed ID: 26250900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxidatively modified glyceraldehyde-3-phosphate dehydrogenase in neurodegenerative processes and the role of low molecular weight compounds in counteracting its aggregation and nuclear translocation.
    Gerszon J; Rodacka A
    Ageing Res Rev; 2018 Dec; 48():21-31. PubMed ID: 30254002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of SPECT Probes for In Vivo Imaging of β-Amyloid and Tau Aggregates in the Alzheimer's Disease Brain].
    Watanabe H
    Yakugaku Zasshi; 2017; 137(11):1361-1365. PubMed ID: 29093372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Vitamin E in the Treatment of Alzheimer's Disease: Evidence from Animal Models.
    Gugliandolo A; Bramanti P; Mazzon E
    Int J Mol Sci; 2017 Nov; 18(12):. PubMed ID: 29168797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhizolutin, a Novel 7/10/6-Tricyclic Dilactone, Dissociates Misfolded Protein Aggregates and Reduces Apoptosis/Inflammation Associated with Alzheimer's Disease.
    Kwon Y; Shin J; Nam K; An JS; Yang SH; Hong SH; Bae M; Moon K; Cho Y; Woo J; Park K; Kim K; Shin J; Kim BY; Kim Y; Oh DC
    Angew Chem Int Ed Engl; 2020 Dec; 59(51):22994-22998. PubMed ID: 32844539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease.
    Morsy A; Trippier PC
    J Alzheimers Dis; 2019; 72(s1):S145-S176. PubMed ID: 31594236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of Alzheimer's amyloid-beta aggregation in-vitro by carbenoxolone: Insight into mechanism of action.
    Sharma S; Nehru B; Saini A
    Neurochem Int; 2017 Sep; 108():481-493. PubMed ID: 28652220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Misfolded proteins as a therapeutic target in Alzheimer's disease.
    Liyanage SI; Weaver DF
    Adv Protein Chem Struct Biol; 2019; 118():371-411. PubMed ID: 31928732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.